The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cironi, Luisa ^a   Petricevic, Tanja ^a   Fernandes Vieira, Victor ^a   Provero, Paolo ^b   Fusco, Carlo ^a   Cornaz, Sandrine ^a   Fregni, Giulia ^a   Letovanec, Igor ^a   Aguet, Michel ^c   Stamenkovic, Ivan ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; AXIN2 PROTEIN, HUMAN; BETA CATENIN; HISTONE DEACETYLASE; ONCOPROTEIN; REPRESSOR PROTEIN; SS18-SSX1 FUSION PROTEIN; T CELL FACTOR PROTEIN; TLE1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL; CELL LINE; CONFOCAL MICROSCOPY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SYNOVIAL SARCOMA; TUMOR CELL LINE; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ANIMALS; AXIN PROTEIN; BETA CATENIN; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HUMANS; MICE; MICROSCOPY, CONFOCAL; ONCOGENE PROTEINS, FUSION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SARCOMA, SYNOVIAL; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84959186223     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22113     Document Type: Article

References (53)

1. Toguchida, J., & Nakayama, T. Molecular genetics of sarcomas: applications to diagnoses and therapy. Cancer Sci. 100, 1573-1580, doi: 10.1111/j.1349-7006.2009.01232.x (2009
2. Haldar, M., Randall, R. L., & Capecchi, M. R. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res. 466, 2156-2167, doi: 10.1007/s11999-008-0340-2 (2008
3. Sandberg, A. A., & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet. 133, 1-23 (2002
4. Ishida, M., Tanaka, S., Ohki, M., & Ohta, T. Transcriptional co-Activator activity of SYT is negatively regulated by BRM and Brg1. Genes Cells. 9, 419-428, doi: 10.1111/j.1356-9597.2004.00737.x (2004
5. Kato, H., et al. SYT associates with human SNF/SWI complexes and the C-Terminal region of its fusion partner SSX1 targets histones. J Biol Chem. 277, 5498-5505 (2002
6. Nagai, M., et al. Analysis of transforming activity of human synovial sarcoma-Associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA. 98, 3843-3848 (2001
7. Pretto, D., et al. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene. 25, 3661-3669, doi: 10.1038/sj.onc.1209413 (2006
8. Fukukawa, C., et al. Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene. 28, 1110-1120, doi: 10.1038/onc.2008.467 (2009
9. Trautmann, M., et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene, doi: 10.1038/onc.2013.443 (2013
10. van Amerongen, R., & Nusse, R. Towards an integrated view of Wnt signaling in development. Development. 136, 3205-3214, doi: 10.1242/dev.033910 (2009
11. Cadigan, K. M., & Peifer, M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harbor perspectives in biology. 1, a002881, doi: 10.1101/cshperspect.a002881 (2009
12. MacDonald, B. T., Tamai, K., & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17, 9-26, doi: 10.1016/j.devcel.2009.06.016 (2009
13. Clevers, H., & Nusse, R. Wnt/beta-catenin signaling and disease. Cell. 149, 1192-1205, doi: 10.1016/j.cell.2012.05.012 (2012
14. Logan, C. Y., & Nusse, R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20, 781-810, doi: 10.1146/.annurev.cellbio.20.010403.113126 (2004
15. Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837-1851 (2000
16. Reya, T., & Clevers, H. Wnt signalling in stem cells and cancer. Nature. 434, 843-850, doi: 10.1038/nature03319 (2005
17. Vijayakumar, S., et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/.beta-catenin target gene, CDC25A. Cancer Cell. 19, 601-612, doi: 10.1016/j.ccr.2011.03.010 (2011
18. Bienz, M., & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell. 103, 311-320 (2000
19. Barham, W., et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov. 3, 1286-1301, doi: 10.1158/2159-8290. CD-13-0138 (2013
20. Saito, T., et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of betacatenin mutations in synovial sarcoma. J Pathol. 192, 342-350, doi: 10.1002/1096-9896(2000)9999: 9999 3.0.CO; 2-R (2000
21. Ng, T. L., et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 18, 68-74, doi: 10.1038/modpathol.3800272 (2005
22. Horvai, A. E., Kramer, M. J., & O'Donnell, R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 130, 792-798, doi: 10.1043/1543-2165(2006)130 [792: CNECWC]2.0.CO; 2 (2006
23. Saito, T., et al. Nuclear beta-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum Pathol. 37, 689-697, doi: 10.1016/j.humpath.2006.01.017 (2006
24. Saito, T., et al. APC mutations in synovial sarcoma. J Pathol. 196, 445-449, doi: 10.1002/path.1066 (2002
25. Sato, H., et al. Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma. Virchows Arch. 438, 23-30 (2001
26. Daniels, D. L., & Weis, W. I. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol. 12, 364-371, doi: 10.1038/nsmb912 (2005
27. Billin, A. N., Thirlwell, H., & Ayer, D. E. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol. 20, 6882-6890 (2000
28. Cadigan, K. M., & Waterman, M. L. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harbor perspectives in biology. 4, doi: 10.1101/cshperspect.a007906 (2012
29. Jho, E. H., et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 22, 1172-1183 (2002
30. Francis, P., et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 8, 73, doi: 10.1186/1471-2164-8-73 (2007
31. Kadoch, C., & Crabtree, G. R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 153, 71-85, doi: 10.1016/j.cell.2013.02.036 (2013
32. Aurade, F., Pinset, C., Chafey, P., Gros, F., & Montarras, D. Myf5, MyoD, myogenin and MRF4 myogenic derivatives of the embryonic mesenchymal cell line C3H10T1/2 exhibit the same adult muscle phenotype. Differentiation. 55, 185-192 (1994
33. Davis, R. L., Weintraub, H., & Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 51, 987-1000 (1987
34. Baird, K., et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 65, 9226-9235 (2005
35. Malanchi, I., et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature. 452, 650-653, doi: 10.1038/nature06835 (2008
36. Ho, R., Papp, B., Hoffman, J. A., Merrill, B. J., & Plath, K. Stage-specific regulation of reprogramming to induced pluripotent stem cells by Wnt signaling and T cell factor proteins. Cell reports. 3, 2113-2126, doi: 10.1016/j.celrep.2013.05.015 (2013
37. Zeng, P. Y., Vakoc, C. R., Chen, Z. C., Blobel, G. A., & Berger, S. L. In vivo dual cross-linking for identification of indirect DNAassociated proteins by chromatin immunoprecipitation. Biotechniques. 41, 694 696, 698 (2006
38. Stamos, J. L., & Weis, W. I. The beta-catenin destruction complex. Cold Spring Harbor perspectives in biology. 5, a007898, doi: 10.1101/.cshperspect.a007898 (2013
39. Xue, J., et al. Tumour suppressor TRIM33 targets nuclear beta-catenin degradation. Nature communications. 6, 6156, doi: 10.1038/.ncomms7156 (2015
40. Finnin, M. S., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 401, 188-193, doi: 10.1038/43710 (1999
41. Date, T., Doiguchi, Y., Nobuta, M., & Shindo, H. Bone morphogenetic protein-2 induces differentiation of multipotent C3H10T1/2 cells into osteoblasts, chondrocytes, and adipocytes in vivo and in vitro. J Orthop Sci. 9, 503-508, doi: 10.1007/s00776-004-0815-2 (2004
42. Haas, A. R., & Tuan, R. S. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function. Differentiation. 64, 77-89, doi: 10.1046/j.1432-0436.1999.6420077.x (1999
43. Komaki, M., Asakura, A., Rudnicki, M. A., Sodek, J., & Cheifetz, S. MyoD enhances BMP7-induced osteogenic differentiation of myogenic cell cultures. J Cell Sci. 117, 1457-1468, doi: 10.1242/jcs.00965 (2004
44. Tang, Q. Q., Otto, T. C., & Lane, M. D. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA. 101, 9607-9611, doi: 10.1073/pnas.0403100101 (2004
45. Haldar, M., Hancock, J. D., Coffin, C. M., Lessnick, S. L., & Capecchi, M. R. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 11, 375-388 (2007
46. Kramps, T., et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 109, 47-60 (2002
47. Barker, N., et al. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J. 20, 4935-4943, doi: 10.1093/emboj/20.17.4935 (2001
48. Suva, D., Passweg, J., Arnaudeau, S., Hoffmeyer, P., & Kindler, V. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol. 214, 588-594, doi: 10.1002/jcp.21244 (2008
49. Arnaudeau, S., Holzer, N., Konig, S., Bader, C. R., & Bernheim, L. Calcium sources used by post-natal human myoblasts during initial differentiation. J Cell Physiol. 208, 435-445, doi: 10.1002/jcp.20679 (2006
50. Cironi, L., et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One. 4, e7904, doi: 10.1371/journal.pone.0007904 (2009
51. Pisco, A. O., et al. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nature communications. 4, 2467, doi: 10.1038/ncomms3467 (2013
52. Irizarry, R. A., et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003
53. Rao, S., Procko, E., & Shannon, M. F. Chromatin remodeling, measured by a novel real-Time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. Journal of immunology. 167, 4494-4503 (2001